Mr. Wang has 25 years of investment banking experience and is widely recognized as one of the most influential figures and pioneers in China's investment banking industry. He founded CEC Capital Group (formerly known as China eCapital Group) in 2000 and is now chairman and CEO of the firm. Under his leadership, CEC Capital, which has closed over 500 transactions with total deal value exceeding RMB500 billion, has emerged as a leading private investment bank and asset management firm with a core focus on the TMT, consumer and healthcare sectors. 

Mr. Wang started his investment banking career at Goldman Sachs in 1994. Prior to founding CEC Capital, he had spent the previous three years with the Global M&A Group of JP Morgan, where he was responsible for developing and executing a number of large M&A transactions in the Asia-Pacific region. Mr. Wang has a bachelor degree in economics from Harvard College and an MBA from Harvard Business School. He has published extensively in leading Chinese financial press.

Ms. Hong is a founding partner for CEC Capital Group, and leads the healthcare industry group. Under her guidance, CEC Capital has emerged as a leader in the healthcare industry with the largest specialized team of over 50 dedicated healthcare bankers, covering pharma/biotech, medical device, services, digital healthcare, and synthetic biology sectors. CEC works with leading China healthcare players and also has a strong cross-border practice.

Prior to joining CEC Capital, Ms. Hong was with Accenture Strategic Services (formerly Andersen Consulting) in San Francisco. Before receiving her MBA, Ms. Hong worked as an engineer for Merck and worked on several significant projects, including a humanitarian technology transfer of a Recombinant Hepatitis B vaccine to China, and the launch of Crixivan, a protease inhibitor for HIV. 

Ms. Hong has both her MBA and BS in Mechanical Engineering from UC Berkeley.

Mr. Li Gang joined CEC Capital in 2016 and is currently a Partner and Head of Healthcare team of CEC Capital. Mr. Li focuses on serving the world's leading healthcare companies and has rich operational experience and industry insights, especially in investment, financing and M&A of leading companies in Biotech, Life sciences, Medtech, healthcare services, and big data AI industries. Mr. Li has provided professional investment banking services to many outstanding companies in the healthcare industry, including GE, Sanofi, bioMérieux, Google Life Sciences, Fresenius, WuXi App Tec, Haier Group, Arrail Dental, Sanbo Brain Hospital and Bluesail Medical.

Mr. Li once served as the Senior Vice President at CITIC Securities and participated in various projects covering refinancing, overseas M&A, asset restructuring and financial advising services. During his tenure in CITIC Securities, he also directly promoted and participated in the establishment and implementation of several fund and asset management programs.

Mr. Li Jin is a Partner at CEC Capital and Head of the Medtech Division. Since joining CEC Capital in 2020, Mr. Li has led the team to complete numerous financing transactions in Medtech, including notable deals such as WuXi Diagnostics, GenomePrecision Tech, b-ONE, NuProbe, Visionmedicals, and UnionStrong Tech. Before joining CEC Capital, he worked for BGI Co-win, focusing on private equity investments.

Mr. Bin Wang is currently serving as the Managing Director and Head of the Healthcare Services Team at CEC Capital. Since joining CEC Capital in 2018, Mr. Wang has demonstrated a profound understanding and extensive coverage of the healthcare services sector, leading the team to complete numerous financing transactions for companies such as Sanbo Brain Hospital, Tencent Doctor Work, Laoken Medical, Sunny Dental, Shanghai Donglei Brain Hospital, EverCare, Nubo Medical, Left Hand Doctor, Diagens. Prior to joining CEC Capital, he worked at Silver Mountain Capital, focusing on private equity investments.

Ms. Jieying Liao is currently serving as the Managing Director and Head of the Synthetic Biology Team at CEC Capital. She specializes in serving companies in the Synthetic Biology sector and related upstream and downstream industries. With a diverse background in research, industry, and investment, Ms. Liao has been instrumental in private equity investments in the healthcare industry at Cash Capital, representing projects such as Mabworks Biotech, Thousand Oaks Biologics, INNOGEN, RNACure, TIAN JIAN, Biocreatech and CASMN.

Mr. Yuan Ye is currently serving as the Managing Director and the Head of GPLP Investment and Exit Services (S Fund Partner) at CEC Capital. Prior to this, he had previously worked at Gopher Asset, Five Star Holdings Group, and China Renaissance as the head of S Fund, and had earlier established the investment methodology and valuation system of S Fund in China. Mr. Yuan Ye is very familiar with the domestic GP&LP ecosystem. He has invested in more than 30 domestic GP’s fund shares, including Sequoia, Dachen, Matrix, StoneVC and etc. He has also led several complex Secondary deals, in forms of tender offering, portfolio transaction, structured financing and etc.

Mr. Zhang Xun is currently serving as the Managing Director and Head of Consumer team at CEC Capital. Before joining CEC Capital, he worked in the investment banking departments of J.P. Morgan, China Renaissance Securities, CITIC Securities and Ping An Securities, and has been deeply involved in the consumer industry investment banking business for more than ten years. Mr. Zhang Xun is very familiar with various products in domestic and overseas capital markets, and has been responsible for many private placements, IPOs, follow-ons, bond issuances and (cross-border) M&A projects for onshore/offshore listed/private clients.

Ms. Maggie Qi is the head of the ECM of CEC Capital and has nearly ten years of investment bank experience in capital markets. Its team has the ability to cover more than 6,000 different types of investors at home and abroad, and provides in-depth services of "capital + industry" for customers in different fields of service, including equity financing, debt financing, industry landed in the local, and domestic and foreign business expansion. Ms. Maggie Qi has accumulated many years of in-depth coverage and cooperation experience in the fields of national background/government background investment institutions, listed companies, large enterprise groups, state enterprise and VC/PE. Led and finished:  4Paradigm、Sunwoda、BIRENTECH、SPICHE、汇付天下、AutoX、Lenovo and other leading enterprise.